Kiniksa Pharmaceuticals International (KNSA) Cash from Financing Activities (2018 - 2026)

Kiniksa Pharmaceuticals International's Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 119.4% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.3 million (up 218.08% YoY) and the FY2025 annual result came in at $33.0 million, up 169.22% from the prior year.
• Cash from Financing Activities was $6.1 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from $7.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $11.9 million in Q3 2025 and bottomed at -$178000.0 in Q2 2024.
• A 5-year average of $3.3 million and a median of $1.2 million in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities tumbled 212.66% — and 2025, when it jumped 6110.11%.
• Kiniksa Pharmaceuticals International's Cash from Financing Activities stood at $1.2 million in 2022, then tumbled by 41.6% to $695000.0 in 2023, then surged by 208.2% to $2.1 million in 2024, then surged by 257.52% to $7.7 million in 2025, then decreased by 20.7% to $6.1 million in 2026.
• Business Quant data shows KNSA's Cash from Financing Activities at $6.1 million in Q1 2026, $7.7 million in Q4 2025, and $11.9 million in Q3 2025.